Liquidia's Yutrepia Found To Infringe Lung Treatment Patent
A Delaware federal judge has ruled that Liquidia was infringing two claims of a patent covering methods of treating pulmonary hypertension associated with interstitial lung disease by seeking approval to market...To view the full article, register now.
Already a subscriber? Click here to view full article